{
  "pmcid": "1894940",
  "sha256": "780e7c4a099cc68e6ab2d675db222ed5877bb54d624979de0e2e5a407b39fd50",
  "timestamp_utc": "2025-11-09T23:44:14.864686+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.038378947368425,
    "reading_ease": 17.850136842105286,
    "word_count": 250
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of COX-2 Inhibition in Acute Inflammatory Pain"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included adults aged 18-45 with no contraindications to NSAIDs."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive rofecoxib, ibuprofen, or placebo."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study explores the impact of selective COX-2 inhibition on gene expression in a clinical model of acute inflammatory pain."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was gene expression changes, measured over 24 hours post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "150 participants were randomised: 50 to rofecoxib, 50 to ibuprofen, and 50 to placebo, recruited between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was intention-to-treat."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The mean difference in ANXA3 expression was 2.5 (95% CI 1.8 to 3.2; p < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 2% in the rofecoxib group and 1% in the ibuprofen group reporting gastrointestinal side effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01234567"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the National Institutes of Health."
      }
    },
    "total_score": 25,
    "max_score": 25
  }
}